Serum TWEAK Levels in Acne Vulgaris

Status Completed

Clinical Trial Summary

Evaluate the serum level of TWEAK in patients with AV and their relations before and after treatment with isotretinoin.

Clinical Trial Description

Acne vulgaris is a chronic inflammatory disease of the pilosebaceous follicles, characterized by comedones, papules, pustules, cysts, nodules, and occasionally scars. Its pathogenesis includes follicular hyperkeratinization, sebaceous hypersecretion due to androgen stimulation, follicular colonization by Propionibacterium acnes, immune and inflammatory responses. It affects the face, anterior chest, and upper back . Inflammation is regarded as a key component in the pathogenesis of acne . An increase in the activity of the pro inflammatory cytokine, interleukin (IL) 1, is observed before the beginning of hyperproliferation around the uninvolved follicles and is thought to trigger the activation of keratinocyte proliferation. Nuclear factor kappa beta (NF κβ) regulated mRNA gene levels of the cytokines tumour necrosis factor (TNF) α, IL 1 β, IL 8 and IL 10 levels also affected. Isotretinoin (13-cis retinoic acid) is a synthetic analog of vitamin A. Its oral form is prescribed for severe cases which are resistant to other treatments. Tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) belongs to the TNF superfamily. It has an important role in the regulation of cell growth, apoptosis, angiogenesis, and immune reactions. ;

Study Design

Related Conditions & MeSH terms

Acne Vulgaris

Clinical Trial Details

NCT number	NCT05684861
Study type	Interventional
Source	South Valley University
Contact
Status	Completed
Phase	Phase 2
Start date	January 1, 2022
Completion date	January 1, 2023

View Details

See also
Status	Clinical Trial	Phase
Completed	`NCT04321070` - Bio-equivalence Study With Clinical Endpoints in the Treatment of Acne Vulgaris	Phase 1
Recruiting	`NCT05755256` - The Impact of Probiotics on Skin Hydration in Youth With Mild Acne	Phase 2
Completed	`NCT05131373` - Safety, Tolerability, and Immunogenicity of ORI-A-ce001 for the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01445301` - Study STF115287, a Clinical Confirmation Study of GSK2585823 in the Treatment of Acne Vulgaris in Japanese Subjects	Phase 3
Completed	`NCT03303170` - Non-Significant Risk Study of Sebacia Microparticles in the Treatment of Facial Acne Vulgaris	N/A
Completed	`NCT04698239` - Clinical Evaluation of the Safety and Benefits of the Milesman 445 nm Blue Laser on Inflammatory Acne Lesions.	N/A
Completed	`NCT02886715` - A Study Comparing Tazarotene Cream 0.1% to TAZORAC® (Tazarotene) Cream 0.1% and Both to a Placebo Control in the Treatment of Acne Vulgaris	Phase 3
Terminated	`NCT02924428` - Venus Versa Diamondpolar Applicator Treatment Followed by AC Dual Applicator Treatment for Facial Acne Vulgaris	N/A
Not yet recruiting	`NCT02491060` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Not yet recruiting	`NCT02535871` - A Study Comparing the Efficacy and Safety of IDP-121 and IDP-121 Vehicle Lotion in the Treatment of Acne Vulgaris	Phase 3
Not yet recruiting	`NCT02525822` - Study to Compare the Safety and Efficacy of IDP-123 Lotion to Tazorac Cream in the Treatment of Acne Vulgaris	Phase 2
Completed	`NCT02709902` - Study Comparing Adapalene/BP Gel to EPIDUO® FORTE and Both to a Placebo Control in Treatment of Acne Vulgaris	Phase 1
Completed	`NCT02913001` - The Effect of a Low Glycemic Load Diet on Hormonal Markers Associated With Acne	N/A
Completed	`NCT02250430` - A Phase 1 Study Assessing Local Cutaneous Effects of SB204	Phase 1
Completed	`NCT01769664` - A Study Comparing Clindamycin 1%/Benzoyl Peroxide 5% Topical Gel to Duac® Topical Gel in the Treatment of Acne Vulgaris	Phase 1
Completed	`NCT01694810` - Cutaneous Tolerability and Safety of NVN1000 Topical Gel in Healthy Volunteers	Phase 1
Completed	`NCT01727440` - Identifying the Genetic Predictors of Severe Acne Vulgaris and the Outcome of Oral Isotretinoin Treatment	N/A
Completed	`NCT01194375` - A Dose-Ranging Study Evaluating the Safety and Efficacy of IDP-107 in Patients With Acne Vulgaris	Phase 2
Completed	`NCT01706250` - U0289-401: Eight Week, Split-face, Study to Determine and Compare the Efficacy and Tolerability of MAXCLARITY™ II to PROACTIV™	Phase 4
Completed	`NCT00991198` - The Role of Topically Dissolved Oxygen (TDO) to Ameliorate Signs of Photodamage	Phase 2